http://jcps.bjmu.edu.cn

• 【综述】 • 上一篇    下一篇

GLP-1生物学及基于GLP-1的抗糖尿病药物研究

易凡, 李栋, 马伟志, 杜权*   

  1. 北京大学医学部 天然药物及仿生药物国家重点实验室, 北京 100191
  • 收稿日期:2013-01-08 修回日期:2013-01-15 出版日期:2013-01-20 发布日期:2013-01-20
  • 通讯作者: 杜权*

GLP-1 biology and GLP-1 based antidiabetic therapy

Fan Yi, Dong Li, Weizhi Ma, Quan Du*   

  1. State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
  • Received:2013-01-08 Revised:2013-01-15 Online:2013-01-20 Published:2013-01-20
  • Contact: Quan Du*

摘要:

在过去的几十年中, 环境和生活方式的改变使得2型糖尿病患者的数量急剧增加, 其中一个重要的病理基础是胰岛素分泌缺陷。胰高血糖素样肽1(GLP-1)是一种由肠道细胞产生及分泌的多肽激素, 该激素以葡萄糖浓度依赖性方式促进胰岛β细胞分泌胰岛素, 调节血糖水平。研究表明GLP-1是糖尿病治疗中的一个有效靶点, 药物研发目前主要集中于GLP-1受体激动剂和降解酶抑制剂两个方面。以其强大的生物学活性为基础, GLP-1药物在临床上表现出高效、低副作用的显著优势。在此, 我们对GLP-1生物学和基于GLP-1的抗糖尿病药物研发进行综述。

关键词: GLP-1, GLP-1受体, 糖尿病, 肠促胰腺素

Abstract:

Environmental and lifestyle factors together account for the dramatic increase of type 2 diabetes in the past decades, in which defective insulin secretion emerges as the major culprit. Glucagon-like peptide 1 (GLP-1) is a peptide secreted from the intestine in response to nutrient ingestion, and plays an essential role in the regulation of blood glucose level by stimulating glucoses-dependent insulin secretion. Recently, GLP-1 develops to be a viable therapeutic target for the treatment of type 2 diabetes, by means of GLP-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Stemmed from its potent physiological activities, GLP-1-based therapies are clinically efficient and safe for both early and late stages of the disease, with low risk of adverse events. In this review, a comprehensive understanding of GLP-1 biology and the recent development of GLP-1-based antidiabetic therapy are summarized.

Key words: GLP-1, GLP-1 receptor, Diabetes, Incretin hormones

中图分类号: 

Supporting: Foundation item: The National Key Basic Research Program of China (Grant No. 2011CBA01100).
*Corresponding author. Tel.: 86-10-82805780